Receptor flexibility in ligand docking and virtual screening

In silico Lead Discovery

Volumn , Issue , 2011, Pages 99-117

  Miteva, Maria A ^a   Robert, Charles H ^b   Maréchal, Jean Didier ^c   Perahia, David ^d  

^a INSERM   (France)

^b CNRS   (France)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d INSTITUTE FOR INTEGRATIVE BIOLOGY OF THE CELL I2BC   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876886763     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2174/978160805142711101010099     Document Type: Chapter

References (158)

1. Teague, S.J. Implications of protein flexibility for drug discovery. Nat. Rev. Drug Discov. 2003, 2, 527-541.
2. Cavasotto, C.N.; Orry, A.J.; Abagyan, R. The challenge of considering receptor flexibility in ligand docking and virtual screening. Curr. Comput-Aided Drug Design 2005, 1, 423-440.
3. Falke, J.J. ENZYMOLOGY: A moving story. Science 2002, 295, 1480-1481.
4. Testa, B.; Vistoli, G.; Pedretti, A. Musings on ADME predictions and structure-activity relations. Chem. Biodivers 2005, 2, 1411-1427.
5. Cavasotto, C.N.; Abagyan, R.A. Protein flexibility in ligand docking and virtual screening to protein kinases. J. Mol. Biol. 2004, 337, 209-225.
6. Erickson, J.A.; Jalaie, M.; Robertson, D.H.; Lewis, R.A.; Vieth, M. Lessons in molecular recognition: the effects of ligand and protein flexibility on molecular docking accuracy. J. Med. Chem. 2004, 47, 45-55.
7. Alberts, I.L.; Todorov, N.P.; Dean, P.M. Receptor flexibility in de novo ligand design and docking. J. Med. Chem. 2005, 48, 6585-6596.
8. Cozzini, P.; Kellogg, G.E.; Spyrakis, F.; Abraham, D.J.; Costantino, G.; Emerson, A.; Fanelli, F.; Gohlke, H.; Kuhn, L.A.; Morris, G.M.; Orozco, M.; Pertinhez, T.A.; Rizzi, M.; Sotriffer, C.A. Target flexibility: an emerging consideration in drug discovery and design. J. Med. Chem. 2008, 51, 6237-6255.
9. McInnes, C. Virtual screening strategies in drug discovery. Curr. Opin. Chem. Biol. 2007, 11, 494-502.
10. Cavasotto, C.N.; Singh, N. Docking and High Throughput Docking: Successes and the Challenge of Protein Flexibility. Current Computer-Aided Drug Design 2008, 4, 221-234.
11. B-Rao, C.; Subramanian, J.; Sharma, S.D. Managing protein flexibility in docking and its applications. Drug Discov. Today 2009, 14, 394-400.
12. Fritz, T.A.; Tondi, D.; Finer-Moore, J.S.; Costi, M.P.; Stroud, R.M. Predicting and harnessing protein flexibility in the design of species-specific inhibitors of thymidylate synthase. Chem. Biol. 2001, 8, 981-995.
13. Sielecki, T.M.; Boylan, J.F.; Benfield, P.A.; Trainor, G.L. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J. Med. Chem. 2000, 43, 1-18.
14. Davies, T.G.; Bentley, J.; Arris, C.E.; Boyle, F.T.; Curtin, N.J.; Endicott, J.A.; Gibson, A.E.; Golding, B.T.; Griffin, R.J.; Hardcastle, I.R.; Jewsbury, P.; Johnson, L.N.; Mesguiche, V.; Newell, D.R.; Noble, M.E.; Tucker, J.A.; Wang, L.; Whitfield, H.J. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat. Struct. Biol. 2002, 9, 745-749.
15. Hardcastle, I.R.; Arris, C.E.; Bentley, J.; Boyle, F.T.; Chen, Y.; Curtin, N.J.; Endicott, J.A.; Gibson, A.E.; Golding, B.T.; Griffin, R.J.; Jewsbury, P.; Menyerol, J.; Mesguiche, V.; Newell, D.R.; Noble, M.E.; Pratt, D.J.; Wang, L.Z.; Whitfield, H.J. N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2. J. Med. Chem. 2004, 47, 3710-3722.
16. Frembgen-Kesner, T.; Elcock, A.H. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase. J. Mol. Biol. 2006, 359, 202-214.
17. Bowman, A.L.; Lerner, M.G.; Carlson, H.A. Protein flexibility and species specificity in structure-based drug discovery: dihydrofolate reductase as a test system. J. Am. Chem. Soc. 2007, 129, 3634-3640.
18. Birdsall, B.; Feeney, J.; Tendler, S.J.; Hammond, S.J.; Roberts, G.C. Dihydrofolate reductase: multiple conformations and alternative modes of substrate binding. 1989, 7, 2297-2305.
19. Di Santo, R.; Costi, R.; Roux, A.; Artico, M.; Lavecchia, A.; Marinelli, L.; Novellino, E.; Palmisano, L.; Andreotti, M.; Amici, R.; Galluzzo, C.M.; Nencioni, L.; Palamara, A.T.; Pommier, Y.; Marchand, C. Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action. J. Med. Chem. 2006, 49, 1939-1945.
20. Hornak, V.; Simmerling, C. Targeting structural flexibility in HIV-1 protease inhibitor binding. Drug Discov. Today 2007, 12, 132-138.
21. Damm, K.L.; Ung, P.M.; Quintero, J.J.; Gestwicki, J.E.; Carlson, H.A. A poke in the eye: inhibiting HIV-1 protease through its flap-recognition pocket. Biopolymers 2008, 89, 643-652.
22. Amaro, R.E.; Minh, D.D.; Cheng, L.S.; Lindstrom, W.M., Jr.; Olson, A.J.; Lin, J.H.; Li, W.W.; McCammon, J.A. Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design. J. Am. Chem. Soc. 2007, 129, 7764-7765.
23. Cheng, L.S.; Amaro, R.E.; Xu, D.; Li, W.W.; Arzberger, P.W.; McCammon, J.A. Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase. J. Med. Chem. 2008, 51, 3878-3894.
24. Amaro, R.E.; Schnaufer, A.; Interthal, H.; Hol, W.; Stuart, K.D.; McCammon, J.A. Discovery of drug-like inhibitors of an essential RNA-editing ligase in Trypanosoma brucei. Proc. Natl. Acad. Sci. U S A 2008, 105, 17278-17283.
25. Fischer, E. Einfluss der configuration auf die wirkung derenzyme. Ber. Dtsch. Chem. Ges. 1894, 27, 2985-2993.
26. Koshland, D.E. Application of a theory of enzyme specificity to protein synthesis. Proc. Natl. Acad. Sci. USA 1958, 44, 98-104.
27. Linderstrøm-Lang, K.U.; Schellman, J.A. Protein structure and enzyme activity. Academic Press: New York: 1959; Vol. 1, pp. 443-510.
28. Straub, F.B. Formation of the secondary and tertiary structure of enzymes. Adv. Enzymol. Relat. Areas Mol. Biol. 1964, 26, 89-114.
29. Alonso, H.; Bliznyuk, A.A.; Gready, J.E. Combining docking and molecular dynamic simulations in drug design. Med. Res. Rev. 2006, 26, 531-568.
30. Stumpf, M.P.; Thorne, T.; de Silva, E.; Stewart, R.; An, H. J.; Lappe, M.; Wiuf, C. Estimating the size of the human interactome. Proc. Natl. Acad. Sci. U S A 2008, 105, 6959-6964.
31. Kelly, W.; Stumpf, M. Protein-protein interactions: from global to local analyses. Curr. Opin. Biotechnol. 2008, 19, 396-403.
32. Sperandio, O.; Miteva, M.A.; Segers, K.; Nicolaes, G.; Villoutreix, B.O. Screening outside the catalytic site: Inhibition of macromolecular interactions through structure-based virtual ligand screening experiments. The Open Biochemistry Journal 2008, 2, 29-37.
33. Ruffner, H.; Bauer, A.; Bouwmeester, T. Human protein-protein interaction networks and the value for drug discovery. Drug Discov. Today 2007, 12, 709-716
34. Villoutreix, B.O.; Bastard, K.; Sperandio, O.; Fahraeus, R.; Poyet, J.L.; Calvo, F.; Deprez, B.; Miteva, M.A. In silico-in vitro screening of protein-protein interactions: towards the next generation of therapeutics. Curr. Pharm. Biotechnol. 2008, 9, 103-122.
35. Rahuel, J.; Priestle, J.P.; Grutter, M.G. The crystal structures of recombinant glycosylated human renin alone and in complex with a transition state analogue inhibitor. J. Struct. Biol. 1991, 107, 227-236
36. Ma, B.; Shatsky, M.; Wolfson, H.J.; Nussinov, R. Multiple diverse ligands binding at a single protein site: a matter of preexisting populations. Protein Sci. 2002, 11, 184-197
37. Mallya, M.; Phillips, R.L.; Saldanha, S.A.; Gooptu, B.; Brown, S.C.; Termine, D.J.; Shirvani, A.M.; Wu, Y.; Sifers, R.N.; Abagyan, R.; Lomas, D.A. Small molecules block the polymerization of Z alpha1-antitrypsin and increase the clearance of intracellular aggregates. J. Med. Chem. 2007, 50, 5357-5363.
38. Esnouf, R.; Ren, J.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol. 1995, 2, 303-308.
39. Murray, C.W.; Baxter, C.A.; Frenkel, A.D. The sensitivity of the results of molecular docking to induced fit effects: Application to thrombin, thermolysin and neuraminidase. J. Comput. Aided Mol. Des. 1999, 13, 547-562.
40. McGovern, S.L.; Shoichet, B.K. Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes. J. Med. Chem. 2003, 46, 2895-2907.
41. Kallblad, P.; Todorov, N.P.; Willems, H.M.; Alberts, I.L. Receptor flexibility in the in silico screening of reagents in the S1' pocket of human collagenase. J. Med. Chem. 2004, 47, 2761-2767.
42. Floquet, N.; Marechal, J.D.; Badet-Denisot, M.A.; Robert, C.H.; Dauchez, M.; Perahia, D. Normal mode analysis as a prerequisite for drug design: application to matrix metalloproteinases inhibitors. FEBS Lett. 2006, 580, 5130-5136.
43. Floquet, N.; Durand, P.; Maigret, B.; Badet, B.; Badet-Denisot, M.A.; Perahia, D. Collective motions in glucosamine-6-phosphate synthase: influence of ligand binding and role in ammonia channelling and opening of the fructose-6-phosphate binding site. J. Mol. Biol. 2009, 385, 653-664.
44. Rueda, M.; Bottegoni, G.; Abagyan, R. Consistent improvement of cross-docking results using binding site ensembles generated with elastic network normal modes. J. Chem. Inf. Model. 2009, 49, 716-725.
45. Sperandio, O.; Mouawad, L.; Pinto, E.; Villoutreix, B.O.; Perahia, D.; Miteva, M.A. How to choose relevant multiple receptor conformations for virtual screening: a test case of Cdk2 and normal mode analysis. 2010, DOI 10.1007/s00249-010-0592-0.
46. Bouzida, D.; Rejto, P.A.; Arthurs, S.; Colson, A.B.; Freer, S.T.; Gehlhaar, D.K.; Larson, V.; Luty, B.A.; Rose, P.W.; Verkhivker, G.M. Computer simulations of ligand-protein binding with ensembles of protein conformations: a Monte Carlo study of HIV-1 protease binding energy landscapes. Int. J. Quantum. Chem. 1999, 72, 73-84.
47. Barril, X.; Morley, S.D. Unveiling the full potential of flexible receptor docking using multiple crystallographic structures. J. Med. Chem. 2005, 48, 4432-4443.
48. Polgar, T.; Keseru, G.M. Ensemble docking into flexible active sites. Critical evaluation of FlexE against JNK-3 and betasecretase. J. Chem. Inf. Model. 2006, 46, 1795-1805.
49. Totrov, M.; Abagyan, R. Flexible ligand docking to multiple receptor conformations: a practical alternative. Curr. Opin. Struct. Biol. 2008, 18, 178-184.
50. Brooks, B.R.; Bruccoleri, R.E.; Olafson, B.D.; States, D.J.; Swaminathan, S.; Karplus, M. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 1983, 4, 187-217.
51. Cornell, W.D.; Cieplak, P.; Bayly, C.I.; Gould, I.R.; Merz, K.M.; Ferguson, D.M.; Spellmeyer, D.C.; Fox, T.; Caldwell, J.W.; Kollman, P.A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1996, 118, 2309.
52. Lindahl, E.; Hess, B.; van der Spoel, D. GROMACS 3.0: A package for molecular simulation and trajectory analysis. J. Mol. Model. 2001, 7, 306-317.
53. Nelson, M.T.; Humphrey, W.; Gursoy, A.; Dalke, A.; Kale, L.V.; Skeel, R.D.; Schulten, K. NAMD: A parallel, object oriented molecular dynamics program. Int. J. Supercomput. Applic. 1996, 10, 251-268.
54. Knegtel, R.M.; Kuntz, I.D.; Oshiro, C.M. Molecular docking to ensembles of protein structures. J. Mol. Biol. 1997, 266, 424-440.
55. Ferrari, A.M.; Wei, B.Q.; Costantino, L.; Shoichet, B.K. Soft docking and multiple receptor conformations in virtual screening. J. Med. Chem. 2004, 47, 5076-5084.
56. Clark, M.; Guarnieri, F.; Shkurko, I.; Wiseman, J. Grand canonical Monte Carlo simulation of ligand-protein binding. J. Chem. Inf. Model. 2006, 46, 231-242.
57. Metropolis, N.; Rosenbluth, A.W.; Rosenbluth, M.N.; Teller, A.H.; Teller, E. Equations of state calculations by fast computing machines. J. Chem. Phys. 1953, 21, 1087-1092.
58. Kawai, H.; Kikuchi, T.; Okamoto, Y. A prediction of tertiary structures of peptide by the Monte Carlo simulated annealing method. Protein Eng. 1989, 3, 85-94.
59. Yue, S.Y. Distance-constrained molecular docking by simulated annealing. Protein Eng. 1990, 4, 177-184.
60. Caflisch, A.; Fischer, S.; Karplus, M. Docking by Monte Carlo minimization with a solvation correction: Application to an FKBP-substrate complex. 1997, 18, 723-743.
61. Taylor, R.D.; Jewsbury, P.J.; Essex, J.W. FDS: flexible ligand and receptor docking with a continuum solvent model and soft-core energy function. J. Comput. Chem. 2003, 24, 1637-1656.
62. Davis, I.W.; Baker, D. RosettaLigand docking with full ligand and receptor flexibility. J. Mol. Biol. 2009, 385, 381-392.
63. Vieth, M.; Hirst, J.D.; Kolinski, A.; Brooks, C.L. Assessing search strategies for flexible docking. J. Comput. Chem. 1998, 16, 1623-1631.
64. Morris, G.; Goodsell, D.S.; Halliday, R.S.; Huey, R.; Hart, W.E.; Belew, R.K.; Olson, A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1999, 19, 1639-1662.
65. Jones, G.; Willett, P.; Glen, R.C.; Leach, A.R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
66. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009, 30, 2785-2791.
67. Corbeil, C.R.; Englebienne, P.; Moitessier, N. Docking ligands into flexible and solvated macromolecules. 1. Development and validation of FITTED 1.0. J. Chem. Inf. Model. 2007, 47, 435-449.
68. Cui, Q.; Bahar, I., Normal mode analysis: theory and applications to biological and chemical systems. Chapman & Hall, London: 2006.
69. Perahia, D.; Mouawad, L. Computation of low-frequency normal modes in macromolecules: improvements to the method of diagonalization in a mixed basis and application to hemoglobin. Comput. Chem. 1995, 19, 241-246.
70. Cavasotto, C.N.; Kovacs, J.A.; Abagyan, R.A. Representing receptor flexibility in ligand docking through relevant normal modes. J. Am. Chem. Soc. 2005, 127, 9632-9640.
71. Tatsumi, R.; Fukunishi, Y.; Nakamura, H. A hybrid method of molecular dynamics and harmonic dynamics for docking of flexible ligand to flexible receptor. J. Comput. Chem. 2004, 25, 1995-2005.
72. Floquet, N.; M'Kadmi, C.; Perahia, D.; Gagne, D.; Berge, G.; Marie, J.; Baneres, J.L.; Galleyrand, J.C.; Fehrentz, J.A.; Martinez, J. Activation of the Ghrelin Receptor is Described by a Privileged Collective Motion: A Model for Constitutive and Agonist-induced Activation of a Sub-class A G-Protein Coupled Receptor (GPCR). J. Mol. Biol. 2010 395, 769-778.
73. Sander, T.; Liljefors, T.; Balle, T. Prediction of the receptor conformation for iGluR2 agonist binding: QM/MM docking to an extensive conformational ensemble generated using normal mode analysis. J. Mol. Graph. Model. 2008, 26, 1259-1268.
74. May, A.; Zacharias, M. Protein-ligand docking accounting for receptor side chain and global flexibility in normal modes: evaluation on kinase inhibitor cross docking. J. Med. Chem. 2008, 51, 3499-3506.
75. Berendsen, H.J.C.; Hayward, S. Collective protein dynamics in relation to function. Current Opinion in Structural Biology 2000, 10, 165-169.
76. Zacharias, M. Rapid protein-ligand docking using soft modes from molecular dynamics simulations to account for protein deformability: binding of FK506 to FKBP. Proteins 2004, 54, 759-767.
77. Timmers, L.F.; Caceres, R.A.; Dias, R.; Basso, L.A.; Santos, D.S.; de Azevedo, W.F., Jr. Molecular modeling, dynamics and docking studies of purine nucleoside phosphorylase from Streptococcus pyogenes. Biophys. Chem. 2009, 142, 7-16.
78. Chang, M.W.; Lindstrom, W.; Olson, A.J.; Belew, R.K. Analysis of HIV wild-type and mutant structures via in silico docking against diverse ligand libraries. J. Chem. Inf. Model. 2007, 47, 1258-1262.
79. Caflisch, A.; Miranker, A.; Karplus, M. Multiple copy simultaneous search and construction of ligands in binding sites: application to inhibitors of HIV-1 aspartic proteinase. J. Med. Chem. 1993, 36, 2142-2167.
80. Elber, R.; Karplusm, M. Enhanced sampling in molecular dynamics: use of the time-dependent Hartree approximation for a simulation of carbon monoxide diffusion through myoglobin. J. Am. Chem. Soc. 1990, 112, 9161-9175.
81. Wu, G.; Robertson, D.H.; Brooks, C.L.I.; Vieth, M. Detailed analysis of grid-based molecular docking: A case study of CDOCKER-a CHARMM-based MD docking algorithm. J. Comput. Chem. 2003, 24, 1549-1562.
82. Vieth, M.; Cummins, D.J. DoMCoSAR: a novel approach for establishing the docking mode that is consistent with the structure-activity relationship. Application to HIV-1 protease inhibitors and VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 2000, 43, 3020-3032.
83. Wu, G.; Vieth, M. SDOCKER: a method utilizing existing X-ray structures to improve docking accuracy. J. Med. Chem. 2004, 47, 3142-3148.
84. Khandelwal, A.; Lukacova, V.; Comez, D.; Kroll, D. M.; Raha, S.; Balaz, S. A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands. J. Med. Chem. 2005, 48, 5437-5447.
85. Ferrara, P.; Curioni, A.; Vangrevelinghe, E.; Meyer, T.; Mordasini, T.; Andreoni, W.; Acklin, P.; Jacoby, E. New scoring functions for virtual screening from molecular dynamics simulations with a quantum-refined force-field (QRFF-MD). Application to cyclin-dependent kinase 2. J. Chem. Inf. Model. 2006, 46, 254-263.
86. Hoffmann, D.; Kramer, B.; Washio, T.; Steinmetzer, T.; Rarey, M.; Lengauer, T. Two-stage method for protein-ligand docking. J. Med. Chem. 1999, 42, 4422-4433.
87. Wang, J.; Kollman, P.A.; Kuntz, I.D. Flexible ligand docking: a multistep strategy approach. Proteins 1999, 36, 1-19.
88. Sherman, W.; Beard, H.S.; Farid, R. Use of an induced fit receptor structure in virtual screening. Chem. Biol. Drug. Des. 2006, 67, 83-84.
89. Nabuurs, S.B.; Wagener, M.; de Vlieg, J. A flexible approach to induced fit docking. J. Med. Chem. 2007, 50, 6507-6518.
90. Carlson, H.A.; Masukawa, K.M.; Rubins, K.; Bushman, F.D.; Jorgensen, W. L.; Lins, R.D.; Briggs, J.M.; McCammon, J.A. Developing a dynamic pharmacophore model for HIV-1 integrase. J. Med. Chem. 2000, 43, 2100-2114.
91. Kairys, V.; Gilson, M.K. Enhanced docking with the mining minima optimizer: acceleration and side-chain flexibility. J. Comput. Chem. 2002, 23, 1656-1670.
92. Leach, A.R. Ligand docking to proteins with discrete side-chain flexibility. J. Mol. Biol. 1994, 235, 345-356.
93. Frimurer, T.M.; Peters, G.H.; Iversen, L.F.; Andersen, H.S.; Moller, N.P.; Olsen, O.H. Ligand-induced conformational changes: improved predictions of ligand binding conformations and affinities. Biophys. J. 2003, 84, 2273-2281.
94. Hartmann, C.; Antes, I.; Lengauer, T. Docking and scoring with alternative side-chain conformations. Proteins 2009, 74, 712-726.
95. Schnecke, V.; Swanson, C.A.; Getzoff, E.D.; Tainer, J.A.; Kuhn, L.A. Screening a peptidyl database for potential ligands to proteins with side-chain flexibility. Proteins 1998, 33, 74-87.
96. Zavodszky, M.I.; Kuhn, L.A. Side-chain flexibility in protein-ligand binding: the minimal rotation hypothesis. Protein Sci. 2005, 14, 1104-1114.
97. Andrusier, N.; Mashiach, E.; Nussinov, R.; Wolfson, H.J. Principles of flexible protein-protein docking. Proteins 2008, 73, 271-289.
98. Jacobs, D.J.; Rader, A.J.; Kuhn, L.A.; Thorpe, M.F. Protein flexibility predictions using graph theory. Proteins 2001, 44, 150-165.
99. Zavodszky, M.I.; Lei, M.; Thorpe, M.F.; Day, A.R.; Kuhn, L.A. Modeling correlated main-chain motions in proteins for flexible molecular recognition. Proteins 2004, 57, 243-261.
100. Arora, K.; Brooks, C.L., 3rd. Large-scale allosteric conformational transitions of adenylate kinase appear to involve a population-shift mechanism. Proc. Natl. Acad. Sci. U S A 2007, 104, 18496-18501.
101. Lin, J.H.; Perryman, A.L.; Schames, J.R.; McCammon, J.A. The relaxed complex method: Accommodating receptor flexibility for drug design with an improved scoring scheme. Biopolymers 2003, 68, 47-62.
102. Amaro, R.E.; Baron, R.; McCammon, J.A. An improved relaxed complex scheme for receptor flexibility in computer-aided drug design. J. Comput. Aided Mol. Des. 2008, 22, 693-705.
103. Bowman, A.L.; Nikolovska-Coleska, Z.; Zhong, H.; Wang, S.; Carlson, H.A. Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. J. Am. Chem. Soc. 2007, 129, 12809-12814.
104. Damm, K.L.; Carlson, H.A. Exploring experimental sources of multiple protein conformations in structure-based drug design. J. Am. Chem. Soc. 2007, 129, 8225-8235.
105. Wei, B.Q.; Weaver, L.H.; Ferrari, A.M.; Matthews, B.W.; Shoichet, B.K. Testing a flexible-receptor docking algorithm in a model binding site. J. Mol. Biol. 2004, 337, 1161-1182.
106. Huang, S.Y.; Zou, X. Ensemble docking of multiple protein structures: considering protein structural variations in molecular docking. Proteins 2007, 66, 399-421.
107. Huang, S.Y.; Zou, X. Efficient molecular docking of NMR structures: application to HIV-1 protease. Protein Sci. 2007, 16, 43-51.
108. Bolstad, E.S.; Anderson, A.C. In pursuit of virtual lead optimization: the role of the receptor structure and ensembles in accurate docking. Proteins 2008, 73, 566-580.
109. Durdagi, S.; Mavromoustakos, T.; Chronakis, N.; Papadopoulos, M. G. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations. Bioorg. Med. Chem. 2008, 16, 9957-9974.
110. Broughton, H.B. A method for including protein flexibility in protein-ligand docking: improving tools for database mining and virtual screening. J. Mol. Graph. Model. 2000, 18, 247-257.
111. Osterberg, F.; Morris, G.M.; Sanner, M.F.; Olson, A.J.; Goodsell, D.S. Automated docking to multiple target structures: incorporation of protein mobility and structural water heterogeneity in AutoDock. Proteins 2002, 46, 34-40.
112. Bolstad, E.S.; Anderson, A.C. In pursuit of virtual lead optimization: pruning ensembles of receptor structures for increased efficiency and accuracy during docking. Proteins 2009, 75, 62-74.
113. Claussen, H.; Buning, C.; Rarey, M.; Lengauer, T. FlexE: efficient molecular docking considering protein structure variations. J. Mol. Biol. 2001, 308, 377-395.
114. Bottegoni, G.; Kufareva, I.; Totrov, M.; Abagyan, R. Four-dimensional docking: a fast and accurate account of discrete receptor flexibility in ligand docking. J. Med. Chem. 2009, 52, 397-406.
115. Thorsteinsdottir, H.B.; Schwede, T.; Zoete, V.; Meuwly, M. How inaccuracies in protein structure models affect estimates of protein-ligand interactions: computational analysis of HIV-I protease inhibitor binding. Proteins 2006, 65, 407-423.
116. de Azevedo, W.F., Jr.; Dias, R. Experimental approaches to evaluate the thermodynamics of protein-drug interactions. Curr. Drug Targets 2008, 9, 1071-1076.
117. Liu, T.; Lin, Y.; Wen, X.; Jorissen, R.N.; Gilson, M.K. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 2007, 35, D198-201.
118. Guvench, O.; MacKerell, A.D., Jr. Computational evaluation of protein-small molecule binding. Curr. Opin. Struct. Biol. 2009, 19, 56-61.
119. Mobley, D.L.; Dill, K.A. Binding of small-molecule ligands to proteins: "what you see" is not always "what you get". Structure 2009, 17, 489-498.
120. Gilson, M.K.; Zhou, H.X. Calculation of protein-ligand binding affinities. Annu. Rev. Biophys. Biomol. Struct. 2007, 36, 21-42.
121. Woo, H.J.; Roux, B. Calculation of absolute protein-ligand binding free energy from computer simulations. Proc. Natl. Acad. Sci. U S A 2005, 102, 6825-6830.
122. Doudou, S.; Burton, N.A.; Henchman, R.H. Standard free energy of binding from a one-dimensional potential of mean force. J. Chem. Theory Comput. 2009, 5, 909-918.
123. Jorgensen, W.L.; Severance, D.L. Aromatic-aromatic interactions: free-energy profiles for the benzene dimer in water, chloroform, and liquid benzene. J. Am. Chem. Soc. 1990, 112, 4768-4774.
124. Roux, B. The calculation of the potential of mean force using computer simulations. Comp. Phys. Comm. 1995, 91, 275-282.
125. Ytreberg, F.M. Absolute FKBP binding affinities obtained via nonequilibrium unbinding simulations. J. Chem. Phys. 2009, 130, 164906.
126. Hajjar, E.; Perahia, D.; Debat, H.; Nespoulous, C.; Robert, C.H. Odorant binding and conformational dynamics in the odorant-binding protein. J. Biol. Chem. 2006, 281, 29929-29937.
127. Hummer, G.; Szabo, A. Free energy surfaces from single-molecule force spectroscopy. Acc. Chem. Res. 2005, 38, 504-513.
128. Brandsdal, B.O.; Osterberg, F.; Almlof, M.; Feierberg, I.; Luzhkov, V.B.; Aqvist, J. Free energy calculations and ligand binding. Adv. Protein Chem. 2003, 66, 123-158.
129. Shirts, M.R.; Mobley, D.L.; Chodera, J.D. Alchemical free energy computations: Ready for prime time?. Annual Reports in Computational Chemistry 2007, 3, 41-59.
130. Knight, J.L.; Brooks, C.L. Validating charmm parameters and exploring charge distribution rules in structure-based drug design. Journal of Chemical Theory and Computation 2009, 5, 1680-1691.
131. Kim, J.T.; Hamilton, A.D.; Bailey, C.M.; Domaoal, R.A.; Wang, L.; Anderson, K.S.; Jorgensen, W L. FEP-guided selection of bicyclic heterocycles in lead optimization for non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Am. Chem. Soc. 2006, 128, 15372-15373.
132. Michel, J.; Essex, J.W. Hit identification and binding mode predictions by rigorous free energy simulations. J. Med. Chem. 2008, 51, 6654-6664.
133. Blondel, A. Ensemble variance in free energy calculations by thermodynamic integration: theory, optimal "Alchemical" path, and practical solutions. J. Comput. Chem. 2004, 25, 985-993.
134. Shyu, C.; Ytreberg, F.M. Reducing the bias and uncertainty of free energy estimates by using regression to fit thermodynamic integration data. J. Comput. Chem. 2009, 30, 2297-2304.
135. Mobley, D.L.; Graves, A.P.; Chodera, J.D.; McReynolds, A.C.; Shoichet, B.K.; Dill, K.A. Predicting absolute ligand binding free energies to a simple model site. J. Mol. Biol. 2007, 371, 1118-1134.
136. Boyce, S.E.; Mobley, D.L.; Rocklin, G.J.; Graves, A.P.; Dill, K.A.; Shoichet, B.K. Predicting Ligand Binding Affinity with Alchemical Free Energy Methods in a Polar Model Binding Site. J. Mol. Biol. 2009, 394, 747-763.
137. Aqvist, J.; Luzhkov, V.B.; Brandsdal, B.O. Ligand binding affinities from MD simulations. Acc. Chem. Res. 2002, 35, 358-365.
138. Almlöf, M.; Brandsdal, B.O.; Aqvist, J. Binding affinity prediction with different force fields: examination of the linear interaction energy method. J. Comput. Chem. 2004, 25, 1242-1254.
139. Alam, M.A.; Naik, P.K. Applying linear interaction energy method for binding affinity calculations of podophyllotoxin analogues with tubulin using continuum solvent model and prediction of cytotoxic activity. Journal of Molecular Graphics & Modelling 2009, 27, 930-943.
140. Orrling, K.M.; Marzahn, M.R.; Gutierrez-de-Teran, H.; Aqvist, J.; Dunn, B.M.; Larhed, M. alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases. Bioorg. Med. Chem. 2009, 17, 5933-5949.
141. Srinivasan, J.; Cheatham, T.E.; Cieplak, P.; Kollman, P.A.; Case, D.A. Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate - DNA helices. J. Am. Chem. Soc. 1998, 120, 9401-9409.
142. Luo, H.; Sharp, K. On the calculation of absolute macromolecular binding free energies. Proc. Natl. Acad. Sci. U S A 2002, 99, 10399-10404.
143. Wong, S.; Amaro, R.E.; McCammon, J.A. MM-PBSA Captures Key Role of Intercalating Water Molecules at a Protein-Protein Interface. J. Chem. Theory Comput. 2009, 5, 422-429.
144. Chang, C.E.; Chen, W.; Gilson, M.K. Ligand configurational entropy and protein binding. Proc. Natl. Acad. Sci. U S A 2007, 104, 1534-1539.
145. Swanson, J.M.; Henchman, R.H.; McCammon, J.A. Revisiting free energy calculations: a theoretical connection to MM/PBSA and direct calculation of the association free energy. Biophys. J. 2004, 86, 67-74.
146. Gohlke, H.; Case, D.A. Converging free energy estimates: MM-PB(GB)SA studies on the protein-protein complex Ras-Raf. J. Comput. Chem. 2004, 25, 238-250.
147. Michel, J.; Tirado-Rives, J.; Jorgensen, W.L. Energetics of Displacing Water Molecules from Protein Binding Sites: Consequences for Ligand Optimization. J. Am. Chem. Soc. 2009, 131, 15403-15411.
148. Deng, Y.; Roux, B. Computation of binding free energy with molecular dynamics and grand canonical Monte Carlo simulations. J. Chem. Phys. 2008, 128, 115103.
149. ten Brink, T.; Exner, T.E. Influence of protonation, tautomeric, and stereoisomeric states on protein-ligand docking results. J. Chem. Inf. Model. 2009, 49, 1535-1546.
150. Ritschel, T.; Hoertner, S.; Heine, A.; Diederich, F.; Klebe, G. Crystal structure analysis and in silico pKa calculations suggest strong pKa shifts of ligands as driving force for high-affinity binding to TGT. Chembiochem 2009, 10, 716-727.
151. Jiao, D.; Golubkov, P.A.; Darden, T.A.; Ren, P. Calculation of protein-ligand binding free energy by using a polarizable potential. Proc. Natl. Acad. Sci. U S A 2008, 105, 6290-6295.
152. Khoruzhii, O.; Donchev, A.G.; Galkin, N.; Illarionov, A.; Olevanov, M.; Ozrin, V.; Queen, C.; Tarasov, V. Application of a polarizable force field to calculations of relative protein-ligand binding affinities. Proc. Natl. Acad. Sci. U S A 2008, 105, 10378-10383.
153. Schames, J.R.; Henchman, R.H.; Siegel, J.S.; Sotriffer, C.A.; Ni, H.; McCammon, J.A. Discovery of a novel binding trench in HIV integrase. J. Med. Chem. 2004, 47, 1879-1881.
154. Lin, J.H.; Perryman, A.L.; Schames, J.R.; McCammon, J.A. Computational drug design accommodating receptor flexibility: the relaxed complex scheme. J. Am. Chem. Soc. 2002, 124, 5632-5633.
155. Tang, J.; Park, J.G.; Millard, C.B.; Schmidt, J.J.; Pang, Y.P. Computer-aided lead optimization: improved small-molecule inhibitor of the zinc endopeptidase of botulinum neurotoxin serotype A. PLoS One 2007, 2, e761.
156. Hu, X.; Prehna, G.; Stebbins, C.E. Targeting plague virulence factors: a combined machine learning method and multiple conformational virtual screening for the discovery of Yersinia protein kinase A inhibitors. J. Med. Chem. 2007, 50, 3980-3983.
157. Degliesposti, G.; Kasam, V.; Da Costa, A.; Kang, H.K.; Kim, N.; Kim, D.W.; Breton, V.; Kim, D.; Rastelli, G. Design and discovery of plasmepsin II inhibitors using an automated workflow on large-scale grids. ChemMedChem 2009, 4, 1164-1173.
158. Hritz, J.; de Ruiter, A.; Oostenbrink, C. Impact of plasticity and flexibility on docking results for cytochrome P450 2D6: a combined approach of molecular dynamics and ligand docking. J. Med. Chem. 2008, 51, 7469-7477.